Insmed (INSM) Stock: Buy, Sell, or Hold?
INSM - Insmed, Inc.
$108.59
-5.55 (-4.86%)
▼
5d:
-10.66%
30d:
-10.63%
90d:
-2.7%
HOLD
MODERATE Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Oct 29, 2026
26d
Get Alerted When INSM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INSM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: INSM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$27.14
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$16.85
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INSM is currently trading at $108.59, which is considered oversold relative to its 30-day fair value range of $117.33 to $126.45. From a valuation perspective, the stock is trading at a discount (Forward PE: 140.2) compared to its historical average (248.2). Remarkably, the market is currently pricing in an annual earnings decline of 17.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, INSM is in a uptrend. The price is currently testing key support at $108.48. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $197.74 (+82.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INSM is in a uptrend. The price is currently testing key support at $108.48. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $197.74 (+82.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$117.33 -
$126.45
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding INSM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.9%)
- BULLISH: Trading 82.1% below Wall St target ($197.74)
- NEUTRAL: Bottoming setup forming (41/100) — watch for confirmation
- CAUTION: 5-day price weakness (-10.7%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$117.33 -
$126.45
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$108.48
Resistance Level
$124.48
Current Trend
Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
140.15
Wall Street Target
$197.74
(+82.1%)
Revenue Growth (YoY)
296.1%
Profit Margin
-76.9%
Valuation Discount vs History
-17.3% cheaper
PE vs Historical
140.2 vs 248.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-17.3%
(market-implied from PE analysis)
1-Year Target
$97.73
(-10%)
2-Year Target
$87.96
(-19%)
3-Year Target
$79.16
(-27%)
3-Yr Target (if PE normalizes)
(PE: 140→248)
$140.19
(+29%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 140.2 to 248.2
Stabilization Target:
$192.31
(+77.1%)
PE Expansion Potential:
+77.1%
Share & Embed Analysis
Last updated: October 02, 2026 6:44 AM ET
Data refreshes hourly during market hours. Next update: 7:44 AM
Data refreshes hourly during market hours. Next update: 7:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INSM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
William Lewis
SELL
10699 shares
2026-04-16
William Lewis
SELL
10699 shares
2026-04-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 51 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$47 | 55 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 45 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 53 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 61 BUY |
Advanced INSM Option Strategies
Professional options setups generated by AI based on today's INSM price and gamma walls.
